| __timestamp | Pfizer Inc. | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 14097000000 | 7461000 |
| Thursday, January 1, 2015 | 14809000000 | 11960000 |
| Friday, January 1, 2016 | 14837000000 | 13108000 |
| Sunday, January 1, 2017 | 14784000000 | 17501000 |
| Monday, January 1, 2018 | 14455000000 | 22472000 |
| Tuesday, January 1, 2019 | 14350000000 | 24286000 |
| Wednesday, January 1, 2020 | 11615000000 | 29689000 |
| Friday, January 1, 2021 | 12703000000 | 38837000 |
| Saturday, January 1, 2022 | 13677000000 | 47489000 |
| Sunday, January 1, 2023 | 14771000000 | 53379000 |
Unleashing insights
In the world of pharmaceuticals, the financial strategies of companies can be as varied as their drug portfolios. Over the past decade, Pfizer Inc. and Xencor, Inc. have demonstrated contrasting approaches to managing Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Pfizer's SG&A expenses have consistently hovered around $14 billion annually, reflecting its expansive global operations and marketing efforts. In contrast, Xencor, a smaller biotech firm, has seen its SG&A costs grow from a modest $7 million in 2014 to over $53 million in 2023, marking a staggering 600% increase. This growth underscores Xencor's aggressive expansion and investment in its administrative capabilities. As these companies navigate the competitive landscape, their financial strategies offer a glimpse into their priorities and future directions.
Comparing SG&A Expenses: Merck & Co., Inc. vs Xencor, Inc. Trends and Insights
Pfizer Inc. and Viatris Inc.: SG&A Spending Patterns Compared
Pfizer Inc. and Sarepta Therapeutics, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Pfizer Inc. and Walgreens Boots Alliance, Inc.
Comparing SG&A Expenses: Pfizer Inc. vs Cytokinetics, Incorporated Trends and Insights
Pfizer Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
argenx SE and Xencor, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs Xencor, Inc.
Operational Costs Compared: SG&A Analysis of Apellis Pharmaceuticals, Inc. and Xencor, Inc.
Comparing SG&A Expenses: Catalyst Pharmaceuticals, Inc. vs Xencor, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Ligand Pharmaceuticals Incorporated or Xencor, Inc.
Breaking Down SG&A Expenses: Agios Pharmaceuticals, Inc. vs Xencor, Inc.